NCT07553442

A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

← Hub

Registry fields

Overall status: RECRUITING
Conditions: Hypertension
Study type: INTERVENTIONAL
Phase: PHASE2
Primary purpose: TREATMENT
Intervention type: DRUG
Interventions: ALN-AGT01 RVR, Placebo, Zilebesiran
Lead sponsor: Alnylam Pharmaceuticals (INDUSTRY)

Cached at: 2026-08-14 23:30:25

View on ClinicalTrials.gov

Brief summary

The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report